

Grifols Accelerates Performance in Q2 and Reaffirms Full Year Guidance

- The second quarter delivers revenue growth of 9.3% cc¹ to EUR 1,818 million, driving the total for H1'24 to EUR 3,444 million, a 7.5% cc increase as compared to H1'23, with all Business Units fueling this growth
- Adjusted EBITDA grew 28% cc to reach EUR 441 million (a 24.2% margin) in Q2'24, contributing to EUR 791 million and a 23.0% margin in H1'24
- Positive free cash flow (EUR 57 million) in Q2'24 driven by working capital optimization
- Reported net profit turned positive to EUR 36 million in H1'24, increasing by EUR 106 million compared to H1'23. Net income excl. one-offs amounted to EUR 152 million
- Leverage ratio declined to 5.5x, driven by EBITDA improvement and the €1.6 billion cash inflow from the SRAAS divestment completed in June
- Reaffirmed guidance for 2024

Barcelona, Spain – July 30, 2024 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today reported solid financial results for the first half of 2024 on the back of a strong second quarter.

Thomas Glanzmann, Executive Chairman, remarked, *“We are pleased to have delivered strong quarterly performance and to reaffirm our guidance for the full year 2024. We remain focused on strengthening our governance and executing our strategy, including debt management. The successful closing of the SRAAS deal, as part of the strategic alliance with Haier, serves as a testament to this, and we expect it will also drive opportunities in China’s fast-growing plasma and diagnostics market.”*

Nacho Abia, Chief Executive Officer, added, *“Thanks to the hard work of the Grifols team, I’m pleased to report that in the second quarter we achieved positive free cash flow, significant sequential EBITDA expansion and near double-digit revenue growth. As we move into the second half of the year, we remain laser-focused on implementing our disciplined approach to operational excellence and cost management to further improve free cash flow generation and deliver sustainable profitability.”*

Business Segment Performance

In the first half of 2024, total revenue reached EUR 3,444 million, a year-over-year increase of 7.5% cc, on the back of an accelerated growth in the second quarter of +9.3% cc spread across all Business Units.

Biopharma delivered 8.9% cc growth in the first half of 2024 with an 8.4% growth in the second quarter. The immunoglobulin franchise grew by 13.1% cc in the first six months of the year (+13.7%

Note: For comparative purposes with H1'24, the financial statements for H1'23 have been re-expressed according to the Inside Information released on July 30, 2024, and further disclosed in accordance with Note 2(d) of the Consolidated Interim Financial Statements for H1'24

¹ Operating or constant currency (cc) excludes changes rate variations reported in the period

cc in the quarter), supported by increasing demand in key regions and continued strong adoption of our subcutaneous immunoglobulin, Xembify®, which surged almost 60% cc in the first half, driven by its performance in the U.S. and its successful commercialization in European countries.

Additionally, albumin revenues grew by 9.6% cc (+11.9% in the quarter) driven by increased demand in China. Alpha-1 and Specialty proteins were flat including the strategic switch of specialty pharma partner in the U.S. during Q2'24 to strengthen the value proposition for Alpha-1 patients for the future.

Diagnostic sales amounted to EUR 322 million in the first half of the year, increasing by 1.9% cc like-for-like² (-3.7% cc reported) and driven by a 1.2% cc uptick in the second quarter on the back of strong Blood Typing Solutions (+14.0% cc) and Immunoassay Donor Screening (+7.6% cc).

Bio Supplies' revenue increase by 32.6% cc resulting in EUR 110 million for the first half of 2024.

Plasma supply continued to increase in the first half of 2024, while cost per liter (CPL) stabilized in the second quarter following a 2% decline in March 2024 compared to December 2023, which added up to the 22% drop since the peak of July 2022. Overall, outlook for plasma remains positive, with significant opportunities for further cost reductions triggered by current initiatives focused on increasing efficiencies, streamlining operations and digitization.

Financial Performance and Leverage

Adjusted EBITDA for the second quarter of 2024 amounted to EUR 441 million, with a 24.2% margin and a 27.9% growth at constant currency. For the first half of the year, it reached EUR 791 million, achieving a 23.0% margin and a 24.1% growth at constant currency. This performance reflects strong operational execution, cost-per-liter reduction in the second half of 2023, and higher fixed-cost absorption in the first half of 2024.

Reported EBITDA for the second quarter reached EUR 414 million and EUR 724 million in the first half, with margins of 22.8% and 21.0%, respectively. Reported EBITDA for the first half mainly included EUR 44 million of non-recurring transaction and restructuring costs and EUR 22 million from the Biotest Next Level (BNL) project³.

Reported net profit turned positive to EUR 36 million in the first half of 2024 from negative EUR (70) million in the same period last year. **Net income excl. one-offs** amounted to EUR 152 million.

Free cash flow generation continues to be Grifols' top priority. Positive free cash flow of EUR 57 million in the second quarter is indicative of the significant sequential improvement expected throughout the year. Working capital improvements, driven by optimized inventory levels, were the largest contributors to the strong free cash flows in the quarter.

Deleveraging remains a key priority for Grifols, and the company made significant progress in the second quarter using the proceeds from the successfully completed SRAAS transaction to lower the company's leverage ratio to 5.5x.

² Excluding the EUR 19 million commercial true-up in Immunoassay Donor Screening (formerly Recombinant proteins) from the first quarter of 2023

³ Biotest Next Level (BNL) is a one-off project aimed to increase production capacity in Dreieich, Germany

Net financial debt as per the Credit Facility stood at EUR 8,262 million. This amount does not include the impact of the financial obligations related to leasing, primarily of plasma centers (IFRS 16) – the related impact is EUR 1,134 million as of June 30, 2024. Therefore, net financial debt as per Balance Sheet was EUR 9,396 million.

As of June 30, 2024, and excluding the EUR 1.6 billion net proceeds from the SRAAS transaction, Grifols had a **liquidity position** of EUR 915 million, with a **cash position** of EUR 568 million.

FY24 Guidance

REVENUE (at cc)	
Total revenue growth	7%+
Biopharma revenue growth	8-10%
EBITDA adjusted	
EBITDA adjusted	EUR 1,800m+
EBITDA adjusted margin	25-26%

Financial Metrics

(in million EUR)	Q2'24	% vs. PY reported	% vs. PY cc	H1'24	% vs. PY reported	% vs. PY cc
Total revenue	1,818m	+9.3%	+9.3%	3,444m	+6.8%	+7.5%
EBITDA Adjusted	441m	+26.3%	+27.9%	791m	+22.2%	+24.1%
EBITDA margin Adjusted	24.2%	+320bps	-	23.0%	+280bps	-
Free Cash Flow	57m	-	-	(196)m	-	-
Leverage Ratio	5.5x	-	-	5.5x	-	-
Liquidity	915m	-	-	915m	-	-
Net profit	15m	-61.1%	-	36m	n/a	-
Net profit excl. one-offs	105m	+127.1%	-	152m	+328.7%	-

Note: All figures are consolidated, including Biotest. Leverage ratio definitions as per Credit Facility

Alternative Performance Measures (APMs)

This document contains the following Alternative Performance Measures (APMs): Consolidated EBITDA Reported, Consolidated EBITDA Adjusted, Leverage Ratio as per the Credit Facility, Net Debt as per the Credit Facility, Free Cash Flow, Working Capital, and non-recurring items. For further details on the definition, explanation on the use, and reconciliation of APMs, please see the Appendix of the Presentation as well as the “Alternative Performance Measures” document from our website www.grifols.com/en/investors.

CONFERENCE CALL

Grifols will host a conference call today, Tuesday, July 30, 2024, at 6:30 pm CET / 12:30 pm EST to provide a Business Update and its Half Year 2024 Financial Results. To view and listen to the webcast and view the presentation, click on [Grifols Q2'24 Results](#) or visit the website www.grifols.com/en/investors. Participants are advised to register in advance of the conference call.

The transcript and webcast replay of the call will be available on the web site at www.grifols.com/en/investors within 24 hours after the end of the live conference call.

INVESTORS:

INVESTORS RELATIONS & SUSTAINABILITY

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

MEDIA CONTACTS:

Grifols Press Office media@grifols.com / Tel. +34 93 571 00 02
Spain Duomo Comunicación Tel.: +34 91 311 92 89 – +34 91 311 92 90 Raquel Lumbreras (M. +34 659 572 185) Raquel_lumbreras@duomocomunicacion.com Borja Gómez (M. +34 650 402 225) Borja_gomez@duomocomunicacion.com

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2023, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

GRIFOLS

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit www.grifols.com

Forward-Looking Statements

This note contains forward-looking information and statements about Grifols based on current assumptions and forecast made by Grifols management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expected", "potential", "estimates" and similar expressions.

Although Grifols believes that the expectations reflected in such forward-looking statements are reasonable, various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Company and the estimates given here. These factors include those discussed in our public reports filed with the Comisión Nacional del Mercado de Valores and the Securities and Exchange Commission, which are accessible to the public. The Company assumes no liability whatsoever to update these forward-looking statements or conform them to future events or developments. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Grifols.

